Trials / Completed
CompletedNCT02960490
A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study in rheumatoid arthritis participants inadequately responding to biologics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E6011 | subcutaneous administration |
| DRUG | Placebo | subcutaneous administration |
Timeline
- Start date
- 2016-11-26
- Primary completion
- 2018-05-16
- Completion
- 2019-11-25
- First posted
- 2016-11-09
- Last updated
- 2021-08-23
- Results posted
- 2021-08-23
Locations
45 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02960490. Inclusion in this directory is not an endorsement.